{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-22-023969","form_type":"8-K","ticker":"OPRX","cik":"0001448431","company_name":"OptimizeRx Corp","filed_at":"2022-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:04:00.763838+00:00","generated_at":"2026-06-26T00:35:01.244047+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"OptimizeRx Q1 revenue up 22% to $13.7M; GAAP net loss widens to $3.8M","bullets":["Revenue $13.7M, +22% YoY; gross margin 59% vs 55%.","GAAP net loss $3.8M ($0.21 per share) vs loss $0.6M ($0.04) in Q1 2021.","Non-GAAP net loss $0.1M ($0.01 per share); cash $89.0M.","Reaffirmed FY2022 revenue guidance $80-85M (31-39% growth) and gross margin 57-60%.","Completed EvinceMed acquisition, a specialty drug prescription initiation platform."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-22-023969","json":"https://secwatch.observer/filing/0001213900-22-023969.json","markdown":"https://secwatch.observer/filing/0001213900-22-023969.md","text":"https://secwatch.observer/filing/0001213900-22-023969.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1448431/000121390022023969/0001213900-22-023969-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1448431/000121390022023969/ea159377-8k_optimizerx.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T00:35:01.244047+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}